AstraZeneca's IMFINZI plus enfortumab vedotin reduced disease progression/recurrence risk by 49% and mortality by 42% in muscle-invasive bladder ...

Wind generation on the ISO New England grid averaged 68% higher across the first nine months of 2026 than in the same months ...

Msd announced today that the European Commission has approved pembrolizumab in combination with enfortumab vedotin, as neoadjuvant treatment and subsequently, after radical cystectomy, as adjuvant ...

In the study, pembrolizumab plus enfortumab vedotin as perioperative treatment demonstrated a statistically significant improvement in event-free survival (Efs), reducing the risk of Efs events by 47% ...

Bacillus Calmette-Guerin (BCG), a vaccine widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia, according to new findings in a study ...

Handheld Point-of-Care Ultrasound Market worth USD 586.3 million in 2026 is growing at a CAGR of 11.5% to reach USD 1,747.5 million by 2036. GE HealthCare Technologies Inc., Butterfly Network, Inc., ...

A retrospective cohort of 60 patients found that bladder preservation was feasible after a complete response to neoadjuvant ...

Research is now underway by the University of South Wales into the specific needs of this group, as the harm caused by ...

ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive ...

Depending on the combination, the 'boundary' between independence and assistance for toileting differed. In a study that ...